Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal

摘要

If a treatment regimen comprising antisense HIF-1 combined with an appropriate antiangiogenic agent, where tumour cell apoptosis is enhanced and tumour angiogenesis inhibited is administered, tumours may be treated more effectively. Particularly excluded from the treatment regimen is 1) the use of taxol together with an antibody or antigen binding fragment thereof adapted to block the binding of VEGF to its receptor VEGFR2; 2) the use of taxol with antisense survivin; and, 3) medicaments comprising an agent adapted to produce a systemic anti-tumour immune response.